The Lancet

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

Pub Date : 2025-09-18 DOI: 10.1016/s0140-6736(25)01576-4 Linda Stein Gold, April W Armstrong, Robert Bissonnette, Nina Magnolo, Ronald B Vender, Michael Sebastian, Maria Laura Galimberti, Athanasios Tsianakas, Marcelo Arnone, Paul Wallace, Margrit Simon, Josep Riera-Monroig, Sascha Gerdes, Jill Waibel, Alvaro Gonzalez-Cantero, Beate Schwarz, Yayoi Tada, Michael Cecchini, Benjamin Ehst, Leon Kircik, Kim A Papp

Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy

Pub Date : 2025-09-18 DOI: 10.1016/s0140-6736(25)01675-7 Luis Puig

Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study

Pub Date : 2025-09-17 DOI: 10.1016/s0140-6736(25)01636-8 Manuela Ochoa-Urrea, Xi Luo, Laura Vilella, Nuria Lacuey, Shirin Jamal Omidi, Norma J Hupp, Blanca Talavera, Johnson P Hampson, M R Sandhya Rani, Shiqiang Tao, Xiaojin Li, Christina Y Miyake, Licong Cui, Jaison S Hampson, Ganne Chaitanya, Yash Shashank Vakilna, Rup K Sainju, Daniel Friedman, Maromi Nei, Luke Allen, Samden D Lhatoo